tiprankstipranks
Trending News
More News >
Rigel (RIGL)
NASDAQ:RIGL
US Market
Advertisement

Rigel (RIGL) Earnings Dates, Call Summary & Reports

Compare
1,555 Followers

Earnings Data

Report Date
Mar 03, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
1
Last Year’s EPS
0.8
Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 04, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted Rigel Pharmaceuticals' strong financial performance, significant increases in revenue and net product sales, and advancements in their drug development pipeline. Despite the termination of a specific CNS program by Eli Lilly, the overall tone was positive, focusing on growth and expansion opportunities.
Company Guidance
During Rigel Pharmaceuticals' third-quarter 2025 financial conference call, the company provided updated guidance for the year, reflecting a strong commercial performance and strategic advancements in their development pipeline. Total revenue for the third quarter reached $69.5 million, driven by record net product sales of $64.1 million, marking a 65% year-over-year increase. Rigel's updated 2025 revenue guidance now projects total revenue between $285 million and $290 million, up from a previous range of $270 million to $280 million, with net product sales expected to be between $225 million and $230 million. This represents an anticipated growth rate of 55% to 59% compared to 2024. The company also reported a net income of $27.9 million for the quarter and increased their cash balance to $137.1 million. Additionally, Rigel highlighted its progress in the ongoing Phase Ib study of R289 and strategic collaborations for olutasidenib, contributing to a promising outlook for sustained growth and development in hematology and oncology.
Record Revenue and Net Product Sales
Total revenue of $69.5 million for Q3 2025, with record net product sales of $64.1 million, a 65% year-over-year increase. Raised 2025 revenue guidance to $285 million to $290 million, exceeding previous expectations.
Strong Performance of Commercial Products
TAVALISSE generated $44.7 million in net product sales, a 70% increase from Q3 2024. GAVRETO achieved $11.1 million, a 56% increase, and REZLIDHIA reported $8.3 million, a 50% increase.
Pipeline Advancements
Completion of enrollment in the dose escalation phase of the R289 study. First patient enrolled in the dose expansion phase. Strategic collaborations and expansions for olutasidenib in IDH1 mutated AML and glioma.
Financial Discipline and Profitability
Reported net income of $27.9 million for Q3 2025, up from $12.4 million in Q3 2024. Increased cash balance to $137.1 million.

Rigel (RIGL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

RIGL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 03, 2026
2025 (Q4)
1.00 / -
0.8
Nov 04, 2025
2025 (Q3)
0.90 / 1.46
0.7108.57% (+0.76)
Aug 05, 2025
2025 (Q2)
2.58 / 3.28
-0.065566.67% (+3.34)
May 06, 2025
2025 (Q1)
0.09 / 0.63
-0.5226.00% (+1.13)
Mar 04, 2025
2024 (Q4)
0.45 / 0.80
0
Nov 07, 2024
2024 (Q3)
0.06 / 0.70
-0.3333.33% (+1.00)
Aug 06, 2024
2024 (Q2)
-0.29 / -0.06
-0.485.00% (+0.34)
May 07, 2024
2024 (Q1)
-0.29 / -0.50
-0.837.50% (+0.30)
Mar 05, 2024
2023 (Q4)
-0.20 / 0.00
0.1
Nov 07, 2023
2023 (Q3)
-0.71 / -0.30
-1.172.73% (+0.80)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

RIGL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
$28.38$37.85+33.37%
Aug 05, 2025
$24.24$29.81+22.98%
May 06, 2025
$18.26$18.47+1.15%
Mar 04, 2025
$22.08$20.29-8.11%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Rigel (RIGL) report earnings?
Rigel (RIGL) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).
    What is Rigel (RIGL) earnings time?
    Rigel (RIGL) earnings time is at Mar 03, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is RIGL EPS forecast?
          RIGL EPS forecast for the fiscal quarter 2025 (Q4) is 1.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis